29 October 2020
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Directors' dealings as part of the Open Offer, the results of which were announced yesterday:
Martin Whitaker, Chief Executive Officer, subscribed for a total of 11,343 Ordinary Shares at 60 pence per share, including 938 shares to be held in pension schemes for the beneficial interest of his dependent children.
Richard Ross, Chief Scientific Officer subscribed for 3,668 Ordinary Shares at a price of 60 pence per Ordinary Share and his wife (Sarah Ross) subscribed for 4,749 Ordinary Shares at 60 pence per Ordinary Share.
Following the transactions and admission of the new ordinary shares to trading on AIM, the total beneficial interest of Martin Whitaker and his connected parties is 593,823 Ordinary Shares, representing 0.43% of the total voting rights and the total beneficial interest of Richard Ross and his connected parties is 2,221,093 Ordinary Shares, representing 1.61% of the total voting rights.
Details of the full notifications received by the Company are set out below:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Martin Whitaker and dependent children
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Diurnal Group plc
|
|
b)
|
LEI
|
213800I2HNUNZN1LDH29
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary shares
of 5 pence each in Diurnal Group plc
|
|
|
|
|
Identification code
|
GB00BDB6Q760
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of ordinary shares, including shares for the beneficial interest of his children
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
60p
|
11,343
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
As above
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
29 October 2020
|
|
f)
|
Place of the transaction
|
XLON
|
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Richard Ross
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Scientific Officer
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Diurnal Group plc
|
|
b)
|
LEI
|
213800I2HNUNZN1LDH29
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary shares
of 5 pence each in Diurnal Group plc
|
|
|
|
|
Identification code
|
GB00BDB6Q760
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
60p
|
3,668
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
As above
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
29 October 2020
|
|
f)
|
Place of the transaction
|
XLON
|
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Sarah Ross
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Closely associated person to an Executive Director
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Diurnal Group plc
|
|
b)
|
LEI
|
213800I2HNUNZN1LDH29
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of instrument
|
Ordinary shares
of 5 pence each in Diurnal Group plc
|
|
|
|
|
Identification code
|
GB00BDB6Q760
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of ordinary shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
60p
|
4,749
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
As above
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
29 October 2020
|
|
f)
|
Place of the transaction
|
XLON
|
|
For further information, please visit
www.diurnal.co.uk
or contact:
|
|
|
|
|
Diurnal Group plc
|
+44 (0)20 3727 1000
|
|
Martin Whitaker, Chief Executive Officer
|
|
|
Richard Bungay, Chief Financial Officer
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)
|
+44 (0)20 7886 2500
|
|
Corporate Finance: Freddy Crossley, Emma Earl
|
|
|
Corporate Broking: Rupert Dearden
|
|
|
|
|
|
FTI Consulting (Media and Investor Relations)
|
+44 (0)20 3727 1000
|
|
Simon Conway
|
|
|
Victoria Foster Mitchell
|
|
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
